Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

被引：0

作者：

Pugnet, G. ^{[1
,2
]}

Pagnoux, C. ^{[3
]}

Terrier, B. ^{[1
]}

Perrodeau, E. ^{[4
]}

Puechal, X. ^{[1
]}

Karras, A. ^{[5
,16
]}

Khouatra, C. ^{[6
]}

Aumaitre, O. ^{[7
]}

Cohen, P. ^{[1
]}

Maurier, F. ^{[8
]}

Decaux, O. ^{[9
]}

Ninet, J. ^{[10
]}

Gobert, P. ^{[11
]}

Quemeneur, T. ^{[12
,13
]}

Blanchard-Delaunay, C. ^{[14
]}

Godmer, P. ^{[15
]}

Carron, P. -L. ^{[16
]}

Hatron, P. -Y. ^{[17
]}

Limal, N. ^{[18
]}

Hamidou, M. ^{[19
]}

Ducret, M. ^{[20
]}

Daugas, E. ^{[21
]}

Papo, T. ^{[22
]}

Bonnotte, B. ^{[23
,24
]}

Mahr, A. ^{[25
]}

Ravaud, P. ^{[4
]}

Mouthon, L. ^{[1
]}

Guillevin, L. ^{[1
]}

机构：

[1] Univ Paris 05, AP HP, Hop Cochin, Natl Referral Ctr Rare System Autoimmune Dis, Paris, France

[2] Toulouse Univ Hosp, Dept Internal Med, Toulouse, France

[3] Univ Toronto, Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada

[4] Univ Paris 05, Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin,INSERM,U738, Paris, France

[5] Univ Paris 05, Hop Europeen Georges Pompidou, Unite Nephrol, Paris, France

[6] Hop Univ Louis Pradel, Serv Pneumol, Ctr Reference Malad Pulm Rares, Lyon, France

[7] Hop Gabriel Montpied, Ctr Hosp Univ, Div internal Med, Clermont Ferrand, France

[8] Hop Prives Metz, Dept Internal Med, Metz, France

[9] Univ Rennes 1, Hop Sud, Hop Univ Rennes, Dept Med Interne,IGDR,UMR 6290, Rennes, France

[10] Hop Edouard Herriot, Dept Nephrol & Internal Med, Lyon, France

[11] Hop Gen Henri Duffaut, Serv Med Interne & Nephrol, Avignon, France

[12] Ctr Hosp Valenciennes, Dept Nephrol, Valenciennes, France

[13] Ctr Hosp Valenciennes, Dept Med Interne, Valenciennes, France

[14] Hop Niort, Serv Med Interne, Niort, France

[15] Ctr Hosp Bretagne Atlantique Vannes, Dept Internal Med, Vannes, France

[16] Ctr Hosp Univ Grenoble, Serv Nephrol Dialyse & Transplantat, Grenoble, France

[17] Univ Lille Nord France, Ctr Hosp Univ Lille, Hop Claude Huriez, Serv Med Interne,Ctr Natl Reference Sclerodermie, Lille, France

[18] Hop Henri Mondor, AP HP, Serv Med Interne, Ctr Reference Labellise Prise Charge Cytopenies A, F-94010 Creteil, France

[19] Ctr Hosp Univ Hotel Dieu, Dept Med Interne, Nantes, France

[20] Ctr Hosp Annecy, Serv Nephrol, Annecy Le Vieux, France

[21] Univ Paris Diderot, Hop Bichat, Serv Nephrol, INSERM,U699,Dept Hosp Univ FIRE, Paris, France

[22] Hop Xavier Bichat, Dept Med Interne, Paris, France

[23] Univ Bourgogne, Ctr Hosp Univ Dijon, Serv Med Interne & Immunol Clin, IFR100, Dijon, France

[24] INSERM, UMR 1098, Besancon, France

[25] Univ Paris 07, Hosp St Louis, Serv Med Interne, F-75221 Paris 05, France

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2016年 / 34卷 / 03期

关键词：

ANCA-associated vasculitis; maintenance therapy; rituximab; azathioprine; health-related quality of life; CONSENSUS CONFERENCE; SINGLE-CENTER; SHORT-FORM; GRANULOMATOSIS; CYCLOPHOSPHAMIDE; NOMENCLATURE; SF-36;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. Methods. In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. Results. Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demonstrated by SF-36, study patients' baseline HRQOL was significantly impaired compared with age-and sex-matched US norms. At month 24, mean changes from baseline of SF-36 physical component score tended to be better for the rituximab group (+3.95 points, p=0.067) whereas mean changes from baseline of the SF-36 mental component score were significantly better for the azathioprine group (+4.23 points, p=0.041). Conclusion. Azathioprine-treated patients' for AAV maintenance therapy showed a decline in physical abilities when compared to RTX at M24 in the MAINRITSAN trial.

引用

页码：S54 / S59

页数：6

共 50 条

[31] Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement
Geetha, Duvuru
Specks, Ulrich
Stone, John H.
Merkel, Peter A.
Seo, Philip
Spiera, Robert
Langford, Carol A.
Hoffman, Gary S.
Kallenberg, Cees G. M.
St Clair, E. William
Fessler, Barri J.
Ding, Linna
Tchao, Nadia K.
Ikle, David
Jepson, Brett
Brunetta, Paul
Fervenza, Fernando C.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (04): : 976 - 985
[32] Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Jones, Rachel B.
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Dorothy
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 211 - 220
[33] Randomized trial of mycophenolate mofetil vs azathioprine for maintenance therapy in ANCA-associated vasculitis (IMPROVE)
Hiemstra, Thomas
Walsh, Michael
De Groot, Kirsten
Hauser, Thomas
Mahr, Alfred
Pagnoux, Christian
Harper, Lorraine
Savage, Caroline
Tesar, Vladimir
Neumann, Irmgard
Wissing, Karl Martin
Schmitt, Wilhelm
Jayne, David
APMIS, 2009, 117 : 77 - 78
[34] Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis
Benarous, Lucas
Terrier, Benjamin
Berezne, Alice
Dunogue, Bertrand
Laborde-Casterot, Herve
Cohen, Pascal
Puechal, Xavier
Costedoat-Chalumeau, Nathalie
Le Jeunne, Claire
Choudat, Dominique
Mouthon, Luc
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S772 - S772
[35] Future Directions of Maintenance Therapy in ANCA-associated Vasculitis
Esposito, Pasquale
Nescis, Lorenzo
Viazzi, Francesca
CURRENT MEDICINAL CHEMISTRY, 2023, 30 (27) : 3052 - 3059
[36] Induction and maintenance therapy in ANCA-associated systemic vasculitis
Menahem, Solomon
Hiremagalur, Balaji
Mudge, David
Toussaint, Nigel
Walters, Giles
NEPHROLOGY, 2008, 13 : S24 - S36
[37] Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines
Tieu, Joanna
Smith, Rona
Basu, Neil
Brogan, Paul
D'Cruz, David
Dhaun, Neeraj
Flossmann, Oliver
Harper, Lorraine
Jones, Rachel B.
Lanyon, Peter C.
Luqmani, Raashid A.
McAdoo, Stephen P.
Mukhtyar, Chetan
Pearce, Fiona A.
Pusey, Charles D.
Robson, Joanna C.
Salama, Alan D.
Smyth, Lucy
Watts, Richard A.
Willcocks, Lisa C.
Jayne, David R. W.
RHEUMATOLOGY, 2020, 59 (04) : e24 - e32
[38] Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life?
Janneke Tuin
Jan-Stephan F Sanders
Birgit M Buhl
André P van Beek
Coen A Stegeman
Arthritis Research & Therapy, 15
[39] Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life?
Tuin, Janneke
Sanders, Jan-Stephan F.
Buhl, Birgit M.
van Beek, Andre P.
Stegeman, Coen A.
ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
[40] RITAZAREM: AN INTERNATIONAL, OPEN-LABEL, RANDOMISED CONTROLLED TRIAL COMPARING RITUXIMAB WITH AZATHIOPRINE AS MAINTENANCE THERAPY IN RELAPSING ANCA-ASSOCIATED VASCULITIS
Smith, Rona Marie
Arimura, Yoshihiro
Merkel, Peter A.
Jayne, David R. W.
RHEUMATOLOGY, 2017, 56 : 150 - 151

← 1 2 3 4 5 →